The following is a summary of “Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis,” published in the January 2025 issue of Psychiatry by Fountoulakis et al.
cbc.ca on MSN12d
'It changed my life tremendously': P.E.I.'s new ketamine clinic could offer mental health helpKetamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with ...
Inquirer on MSN11d
World’s first anti-depression nasal spray receives FDA approvalThe US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...
Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy ...
Medicaid in Wisconsin has expanded to cover ketamine infusions as of Jan. 1, sparking conversations about the nuances in type ...
The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is made ...
Esketamine should only provide rapid relief ... especially for patients who do not respond to oral antidepressants or cannot tolerate them,” said Johnson & Johnson neuroscientist Bill Martin.
Hosted on MSN14d
FDA approves 'ketamine' nasal spray for depression — here's everything you need to knowA nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback